<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601222</url>
  </required_header>
  <id_info>
    <org_study_id>Z-RZZY-JN-RS</org_study_id>
    <nct_id>NCT02601222</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Runzao Zhiyang Capsule to Treat Chronic Eczema</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guizhou Tongjitang Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Bionovo Medicine Development Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guizhou Tongjitang Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Runzao zhiyang capsule in
      treating chronic eczema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polygoni multiflori Preparata, dried rehmannia root, mulberry leaf, sophora flavescens,
      Honghuoma, for skin itching, acne, constipation due to blood vacuity and wind-dryness, also
      used in clinical treatment of eczema.

      The purpose of this study is to evaluate the efficacy and safety of Runzao zhiyang capsule in
      treating chronic eczema.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficiency(The number of cured cases and cases with marked effect) of disease： Using EASI score decline rate to judge. The decline rate of EASI = (before treatment EASI- After treatment EASI)/ before treatment EASI×100%</measure>
    <time_frame>0,4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The decrease rate of EASI in each visit compare with baseline</measure>
    <time_frame>0,2,4,8,12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the degree of pruritus（test by visual analogue scale） in the follow-up visits compared with baseline</measure>
    <time_frame>0,2,4,8,12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI (Dermatology Life Quality Index) score changes during the follow-up visits compared with baseline.</measure>
    <time_frame>0,2,4,8,12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients (EASI score greater than 10% of the patients before treatment)</measure>
    <time_frame>8,12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI score</measure>
    <time_frame>8,12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessments will be based on adverse event reports.</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety assessments will be based on electrocardiogram, physical examinations, and clinical laboratory tests.</measure>
    <time_frame>0,2,4，8，12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Eczema</condition>
  <arm_group>
    <arm_group_label>Runzao zhiyang capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Runzao zhiyang capsule: 4 pills each time, 3 times a day, oral， Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Runzaozhiyang capsule agent simulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Runzaozhiyang capsule agent simulation:4 pills each time, 3 times a day, oral, Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Runzao zhiyang capsule</intervention_name>
    <description>Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.</description>
    <arm_group_label>Runzao zhiyang capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Runzaozhiyang capsule agent simulation</intervention_name>
    <description>Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.</description>
    <arm_group_label>Runzaozhiyang capsule agent simulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urea cream</intervention_name>
    <description>Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.</description>
    <arm_group_label>Runzao zhiyang capsule</arm_group_label>
    <arm_group_label>Runzaozhiyang capsule agent simulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consistent with diagnostic criteria for chronic eczema(Referring to &quot;the Chinese
             eczema diagnosis and treatment guidelines&quot; in 2011);

          -  Investigator Global Assessment (IGA) score was 2 or 3;

          -  The skin lesions were localized, hypertrophy and dry, and the affected skin area was
             3%~10% of body surface area (estimated by palm method); the diameter of target lesions
             was 2~10cm and located in the limbs or trunk.

          -  The course of chronic eczema is more than 6 months;

          -  Age 18 to 70, males or females;

          -  The Subjects obtain informed consent, participated the trial voluntarily. Procedure to
             obtain informed consent is in accordance with the provisions of Good Clinical
             Practise(GCP).

        Exclusion Criteria:

          -  Subjects with acute eczema, subacute eczema, universal eczema, special type of eczema;

          -  Subjects used corticosteroids, immunosuppressive agents and ultraviolet irradiation in
             4 weeks prior to the enrollment;

          -  Subjects were treated with antihistamine and topical drugs in 2 weeks;

          -  Women in Pregnancy, Lactation, or Planned pregnancy during the test;

          -  Comorbid with severe primary heart, liver, lung, kidney, blood disease, diabetes,
             thyroid disease or a serious disease affecting survival, such as cancer or HIV / AIDS;

          -  Subjects were allergic to test drug ingredients;

          -  Subjects could not give full informed consent because of mental and behavioral
             disorders;

          -  Suspected or identified with a history of alcohol or drug abuse;

          -  Have other diseases or conditions which may reduce the possibility of enrollment or
             complicate the recruiting process based on the investigator judgment. For example,
             working environment changed frequently led to easily lost follow-up;

          -  Have been or currently enrolled in other clinical trials within 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gu heng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermotology hospital, Chinese academy of medical science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gu heng, M.D.</last_name>
    <phone>+86-25-85478045</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Sen, M.D.</last_name>
      <phone>+86-551-62922016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Linfeng, M.D.</last_name>
      <phone>+86-10-63138628</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqin Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Hui, M.D.</last_name>
      <phone>+86-25-85478045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeng Fanqin, M.D.</last_name>
      <phone>+86-20-81332371</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lu Qianjin, M.D.</last_name>
      <phone>0731-85292097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermotology hospital, Chinese academy of medical science</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gu Heng, M.D.</last_name>
      <phone>025-85478045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatology Hospital in Shandong Province</name>
      <address>
        <city>Ji nan</city>
        <state>Shandong</state>
        <zip>250022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Furen, M.D.</last_name>
      <phone>+86-531-87298884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rui Jin Hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Jie, M.D.</last_name>
      <phone>+86-21-54661789</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xu Jinhua, M.D.</last_name>
      <phone>+86-21-52888045</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic eczema</keyword>
  <keyword>efficacy and safety</keyword>
  <keyword>Runzao zhiyang capsule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

